<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624116</url>
  </required_header>
  <id_info>
    <org_study_id>RT2011</org_study_id>
    <nct_id>NCT01624116</nct_id>
  </id_info>
  <brief_title>Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes</brief_title>
  <official_title>A Comparison of Four Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetic Patients and the Effect of Add-On Acarbose on Glycaemic Excursions During Ramadan Fasting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Services Hospital, Lahore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Services Hospital, Lahore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetic patients who fast during Ramadan experience swings in glycaemic control
      between hypoglycaemic troughs and hyperglycaemic spikes. Hence, the dual challenge in fasting
      diabetics is to identify which treatment modality leads to the most stable blood glucose
      levels during a fast and how to smooth out these excursions and reduce risks of fast to a
      minimum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives:

        -  To compare changes in clinical and metabolic parameters from baseline to the end of four
           weeks fasting in Ramadan between four treatment arms:

             -  diet and lifestyle measures alone.

             -  metformin monotherapy.

             -  combination therapy with metformin + sulfonylurea.

             -  combination therapy with metformin + sitagliptin.

        -  To compare the 24 hour CGMS profile during Ramadan fasting in type 2 diabetic patients
           before and after addition of acarbose to these pre-existing sub-maximal hypoglycaemic
           regimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight and fructosamine levels during Ramadan fasting.</measure>
    <time_frame>28 days (Average duration of Ramadan fasting)</time_frame>
    <description>Change in body weight and fructosamine levels from baseline to end of Ramadan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting lipid profile from baseline to end of Ramadan.</measure>
    <time_frame>28 days(average duration of Ramadan)</time_frame>
    <description>Change in fasting lipid profile from baseline to end of Ramadan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ghrelin levels from baseline to end of Ramadan.</measure>
    <time_frame>28days (average duration of Ramadan)</time_frame>
    <description>Change in ghrelin levels from baseline to end of Ramadan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal profile from baseline to end of Ramadan</measure>
    <time_frame>28 days(average duration of Ramadan)</time_frame>
    <description>Change in renal profile from baseline to end of Ramadan.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Diabetes, Type 2</condition>
  <arm_group>
    <arm_group_label>Diet and lifestyle measures alone.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 diabetic subjects on lifestyle counselling as part of diabetes treatment would continue as such during Ramadan. They would receive acarbose on one day to be followed by CGMS for a 24 hour period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 diabetics on biguanide treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Sulphonylurea.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 diabetics on dual oral hypoglycaemics-metformin and glimepiride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 diabetics managed on dual oral hypoglycaemic therapies: metformin and sitagliptin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.</description>
    <arm_group_label>Diet and lifestyle measures alone.</arm_group_label>
    <arm_group_label>Metformin monotherapy</arm_group_label>
    <arm_group_label>Metformin + Sulphonylurea.</arm_group_label>
    <arm_group_label>Metformin + Sitagliptin</arm_group_label>
    <other_name>*Tab.Glucobay 50mg (Bayer).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet and lifestyle</intervention_name>
    <description>Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day</description>
    <arm_group_label>Diet and lifestyle measures alone.</arm_group_label>
    <arm_group_label>Metformin monotherapy</arm_group_label>
    <arm_group_label>Metformin + Sulphonylurea.</arm_group_label>
    <arm_group_label>Metformin + Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose</description>
    <arm_group_label>Metformin monotherapy</arm_group_label>
    <other_name>Tablets Glucophage (Merck)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin/ Glimepride</intervention_name>
    <description>Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD</description>
    <arm_group_label>Metformin + Sulphonylurea.</arm_group_label>
    <other_name>Tablet Getformin 1/500 (Getz Pharma)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin/Sitagliptin</intervention_name>
    <description>Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.</description>
    <arm_group_label>Metformin + Sitagliptin</arm_group_label>
    <other_name>Tab.TreviaMet 50/500 (Getz Pharma)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1c 6.5-9.5%.

          -  Type 2 diabetics on two or less oral hypoglycaemic agents.

        Exclusion Criteria:

          -  Any contraindications either to fasting or to any of the trial medication.

          -  Pregnancy.

          -  Serum creatinine &gt; 1.4 mg/dl.

          -  Serum ALT &gt; twice upper limit normal.

          -  History of pancreatitis, serum amylase &gt; twice upper limit normal.

          -  History of intolerance to acarbose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Khadija Irfan, MBBS,FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Services Hospital.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endocrinology Unit &amp; Diabetes Management Centre, Services Hospital.</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Services Hospital, Lahore</investigator_affiliation>
    <investigator_full_name>Dr Saira Burney</investigator_full_name>
    <investigator_title>Senior Registrar, Endocrinology Unit &amp; Diabetes Management Centre, Services Institute of Medical Sciences,Lahore,Pakistan.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

